Guías antieméticas: ¿hemos incorporado los cambios referentes a carboplatino y antraciclinas?

Redondo Capafons, Susana; Soriano Gutierre, Laura; Dalmau Portulas, Elsa; Barragán Muñoz, Àlex; Martínez Robles, Sergio; Gómez-Valenta, Mònica.
Farm. hosp ; 47(5): 183-189, Septiembre - Octubre 2023. tab, ilus
Artículo en Inglés, Español | IBECS (España) | ID: ibc-225605

Documentos relacionados

  1. Translation of novel antiemetic to sub-Saharan Africa using diffusion of innovation framework.
  2. Black Race Is a Social Construct, and There Is No Biological Mechanism to Justify Differences in Antiemetic Prophylaxis.
  3. Effect of dexamethasone and ramosetron on the prevention of postoperative nausea and vomiting in low-risk patients: a randomized, double-blind, placebo-controlled, multicenter trial.
  4. Antiemetic effects of sclareol, possibly through 5-HT<sub>3</sub> and D<sub>2</sub> receptor interaction pathways: In-vivo and in-silico studies.
  5. Determination of Ondansetron by Spectrofluorimetry: Application to Forced Degradation Study, Pharmaceuticals and Human Plasma.
  6. An assessment of the effects of neurokinin<sub>1</sub> receptor antagonism against nausea and vomiting: Relative efficacy, sites of action and lessons for future drug development.
  7. Clinician perspectives of pregnant women's participation in antiemetic decision-making: A qualitative study.
  8. GPCR large-amplitude dynamics by <sup>19</sup>F-NMR of aprepitant bound to the neurokinin 1 receptor.
  9. What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
  10. Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study.